Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

3.95
+0.930030.79%
Post-market: 4.770.8200+20.76%19:59 EST
Volume:76.07M
Turnover:277.81M
Market Cap:3.89B
PE:-9.51
High:3.99
Open:3.14
Low:3.07
Close:3.02
52wk High:4.27
52wk Low:1.83
Shares:984.97M
Float Shares:194.00M
Volume Ratio:3.29
T/O Rate:39.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4153
EPS(LYR):-0.5931
ROE:78.05%
ROA:-36.89%
PB:-7.42
PE(LYR):-6.66

Loading ...

BRIEF-Initial Data Shows 100% Disease Control in 5 of 5 Patients With Recurrent Glioblastoma Treated With ImmunityBio’s ANKTIVA, NK Cell Therapy Plus Optune Gio Device

Reuters
·
Aug 26, 2025

Immunitybio Shares up 4.9% Premarket After Initial Data From Co's Experimental Cancer Treatment Shows Promise

THOMSON REUTERS
·
Aug 26, 2025

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With Immunitybio’s Anktiva®, Nk Cell Therapy Plus Optune Gio® Device

THOMSON REUTERS
·
Aug 26, 2025

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 19, 2025

ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms

Reuters
·
Aug 19, 2025

Immunitybio Announces Phase 2 Study of Anktiva® in Patients With Long Covid

THOMSON REUTERS
·
Aug 19, 2025

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 14, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Lumentum Holdings, ImmunityBio, V2X

Reuters
·
Aug 13, 2025

BUZZ-ImmunityBio rises after early data for blood cancer cell therapy

Reuters
·
Aug 13, 2025

ImmunityBio Announces Promising Results in Clinical Trial for CD19 CAR-NK Therapy in Non-Hodgkin Waldenstrom Lymphoma Patients

Reuters
·
Aug 13, 2025

Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients With Chemotherapy-Free, First-in-Class Cd19 Car-Nk Immunotherapy

THOMSON REUTERS
·
Aug 13, 2025

Immunitybio Inc - Second Patient Maintains Complete Response at Six Months

THOMSON REUTERS
·
Aug 13, 2025

Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer

Stock Track
·
Aug 11, 2025

Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer

Stock Track
·
Aug 11, 2025

Immunitybio Announces Houston’s Michael E. Debakey Va Medical Center Is Among the First Va Hospitals to Administer Anktiva® to Bladder Cancer Patients

THOMSON REUTERS
·
Aug 11, 2025

ImmunityBio Inc. Faces Securities Fraud Class Action and Shareholder Derivative Litigation Settlement

Reuters
·
Aug 09, 2025

Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.10 a Share, vs. FactSet Est of $0.11 Loss

MT Newswires Live
·
Aug 05, 2025

ImmunityBio Inc. Reports 60% Revenue Increase in Q2 2025, Reduces Net Loss to $222.2 Million

Reuters
·
Aug 05, 2025

Immunitybio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code

THOMSON REUTERS
·
Aug 05, 2025

ImmunityBio Reports Q2 Preliminary Revenue

MT Newswires Live
·
Jul 25, 2025